<DOC>
	<DOCNO>NCT02735902</DOCNO>
	<brief_summary>The main objective study demonstrate single anticoagulant therapy superior combination anticoagulant antiplatelet therapy net clinical benefit estimate 12 month Transcatheter Aortic Valve Intervention ( TAVI ) accord BARC2 criterion ( bleed complication ; Mehran et al 2011 ) VARC2 ( complication ; Kappetein et al 2012 ) ..</brief_summary>
	<brief_title>Anticoagulation Alone Versus Anticoagulation Aspirin Following Transcatheter Aortic Valve Interventions ( 1:1 )</brief_title>
	<detailed_description>The secondary objective study evaluate follow 3 month , 6 month 12 month TAVI group : 1 . Mortality ( cause ) . 2 . Cardiovascular mortality . 3 . The occurrence myocardial infarction . 4 . The occurrence stroke . 5 . The occurrence valve thrombosis . 6 . The occurrence major bleeding ( BARC ≥ 3 ) . 7 . The occurrence minor bleeding ( 2 ≤ BARC &lt; 3 ) . 8 . Treatment compliance .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<criteria>The patient his/her representative must give free informed consent sign consent The patient must insure beneficiary health insurance plan The patient available 12 month followup The patient underwent successful transcutaneous implant procedure aortic valve within past 24 hour The patient receive antivitamin K ( AVK ) treatment percutaneous implantation aortic valve The patient participate another study The patient exclusion period determine previous study The patient his/her representative refuse sign consent It impossible correctly inform patient his/her representative The patient pregnant breastfeed The patient contraindication ( incompatible drug association ) treatment use study The patient coronary stent le 12 month The patient require treatment aspirin antiplatelet agent The patient history aspirin allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>antivitamins K</keyword>
</DOC>